Ayala Pharmaceuticals Inc (ADXS)

[tx_farmer]

Advaxis granted Global BioPharma an exclusive license for the development and commercialization of AXAL for the treatment of cervical cancer in Asia. Global BioPharma is responsible for all development and commercial costs and activities associated with the licensed product in Asian territories. Global BioPharma is a Taiwanese biotechnology company funded by a group of investors led by Taiwan Biotech Co., Ltd., a top five pharmaceutical company in Taiwan.

What is there to report, though. until we have a product approved, based on the above, they are waiting for further advancements. They're not going to start stocking up on inventory and build our secondary manufacturing facility before approval is near. Until then the private investors and venture capitals of gbp are paying 250k yr for the privelage of one day (hopefully) have the rights to manufacture and sell our product if approved (and i thought buying the stock was risky) Supposedly gbp's reach is 84 countries and 3.8 billion people. Not a bad deal for us if gbp can deliver. Mostly just thinking outloud because this collab hasnt been discussed in eons.